The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncology Drugs Market Research Report 2025
Synopsis
The global market for Oncology Drugs was valued at US$ 239850 million in the year 2024 and is projected to reach a revised size of US$ 471950 million by 2031, growing at a CAGR of 10.3% during the forecast period.
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The industry"s leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.
This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global market for Oncology Drugs was valued at US$ 239850 million in the year 2024 and is projected to reach a revised size of US$ 471950 million by 2031, growing at a CAGR of 10.3% during the forecast period.
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The industry"s leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.
This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Oncology Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory or Lung Cancer
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Drugs Market Perspective (2020-2031)
2.2 Global Oncology Drugs Growth Trends by Region
2.2.1 Global Oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oncology Drugs Historic Market Size by Region (2020-2025)
2.2.3 Oncology Drugs Forecasted Market Size by Region (2026-2031)
2.3 Oncology Drugs Market Dynamics
2.3.1 Oncology Drugs Industry Trends
2.3.2 Oncology Drugs Market Drivers
2.3.3 Oncology Drugs Market Challenges
2.3.4 Oncology Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Drugs Players by Revenue
3.1.1 Global Top Oncology Drugs Players by Revenue (2020-2025)
3.1.2 Global Oncology Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oncology Drugs Revenue
3.4 Global Oncology Drugs Market Concentration Ratio
3.4.1 Global Oncology Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Drugs Revenue in 2024
3.5 Global Key Players of Oncology Drugs Head office and Area Served
3.6 Global Key Players of Oncology Drugs, Product and Application
3.7 Global Key Players of Oncology Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Drugs Breakdown Data by Type
4.1 Global Oncology Drugs Historic Market Size by Type (2020-2025)
4.2 Global Oncology Drugs Forecasted Market Size by Type (2026-2031)
5 Oncology Drugs Breakdown Data by Application
5.1 Global Oncology Drugs Historic Market Size by Application (2020-2025)
5.2 Global Oncology Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oncology Drugs Market Size (2020-2031)
6.2 North America Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oncology Drugs Market Size by Country (2020-2025)
6.4 North America Oncology Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Drugs Market Size (2020-2031)
7.2 Europe Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oncology Drugs Market Size by Country (2020-2025)
7.4 Europe Oncology Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Drugs Market Size (2020-2031)
8.2 Asia-Pacific Oncology Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oncology Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Oncology Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Drugs Market Size (2020-2031)
9.2 Latin America Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oncology Drugs Market Size by Country (2020-2025)
9.4 Latin America Oncology Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Drugs Market Size (2020-2031)
10.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oncology Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Oncology Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Drugs Introduction
11.1.4 Roche Revenue in Oncology Drugs Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Details
11.2.2 Celgene Business Overview
11.2.3 Celgene Oncology Drugs Introduction
11.2.4 Celgene Revenue in Oncology Drugs Business (2020-2025)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Oncology Drugs Introduction
11.3.4 Novartis Revenue in Oncology Drugs Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Oncology Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2020-2025)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Oncology Drugs Introduction
11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2020-2025)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oncology Drugs Introduction
11.8.4 Pfizer Revenue in Oncology Drugs Business (2020-2025)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Oncology Drugs Introduction
11.9.4 Amgen Revenue in Oncology Drugs Business (2020-2025)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Oncology Drugs Introduction
11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2020-2025)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Oncology Drugs Introduction
11.11.4 AbbVie Revenue in Oncology Drugs Business (2020-2025)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Details
11.12.2 Takeda Business Overview
11.12.3 Takeda Oncology Drugs Introduction
11.12.4 Takeda Revenue in Oncology Drugs Business (2020-2025)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Details
11.13.2 Astellas Business Overview
11.13.3 Astellas Oncology Drugs Introduction
11.13.4 Astellas Revenue in Oncology Drugs Business (2020-2025)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Details
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Oncology Drugs Introduction
11.14.4 Ipsen Revenue in Oncology Drugs Business (2020-2025)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Details
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Oncology Drugs Introduction
11.15.4 Sanofi Revenue in Oncology Drugs Business (2020-2025)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Details
11.16.2 Bayer Business Overview
11.16.3 Bayer Oncology Drugs Introduction
11.16.4 Bayer Revenue in Oncology Drugs Business (2020-2025)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Details
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Oncology Drugs Introduction
11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2020-2025)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Details
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Drugs Introduction
11.18.4 Teva Revenue in Oncology Drugs Business (2020-2025)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Details
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Drugs Introduction
11.19.4 Otsuka Revenue in Oncology Drugs Business (2020-2025)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Details
11.20.2 Eisai Business Overview
11.20.3 Eisai Oncology Drugs Introduction
11.20.4 Eisai Revenue in Oncology Drugs Business (2020-2025)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Details
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Oncology Drugs Introduction
11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2020-2025)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Details
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Oncology Drugs Introduction
11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2020-2025)
11.22.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Immunotherapy (Biologic Therapy)
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Others
Table 7. Global Oncology Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Oncology Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Oncology Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Oncology Drugs Market Share by Region (2020-2025)
Table 11. Global Oncology Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Oncology Drugs Market Share by Region (2026-2031)
Table 13. Oncology Drugs Market Trends
Table 14. Oncology Drugs Market Drivers
Table 15. Oncology Drugs Market Challenges
Table 16. Oncology Drugs Market Restraints
Table 17. Global Oncology Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Oncology Drugs Market Share by Players (2020-2025)
Table 19. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2024)
Table 20. Ranking of Global Top Oncology Drugs Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Oncology Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Oncology Drugs, Headquarters and Area Served
Table 23. Global Key Players of Oncology Drugs, Product and Application
Table 24. Global Key Players of Oncology Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Oncology Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Oncology Drugs Revenue Market Share by Type (2020-2025)
Table 28. Global Oncology Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Oncology Drugs Revenue Market Share by Type (2026-2031)
Table 30. Global Oncology Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Oncology Drugs Revenue Market Share by Application (2020-2025)
Table 32. Global Oncology Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Oncology Drugs Revenue Market Share by Application (2026-2031)
Table 34. North America Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Oncology Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Oncology Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Oncology Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Oncology Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Oncology Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 49. Roche Company Details
Table 50. Roche Business Overview
Table 51. Roche Oncology Drugs Product
Table 52. Roche Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 53. Roche Recent Development
Table 54. Celgene Company Details
Table 55. Celgene Business Overview
Table 56. Celgene Oncology Drugs Product
Table 57. Celgene Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 58. Celgene Recent Development
Table 59. Novartis Company Details
Table 60. Novartis Business Overview
Table 61. Novartis Oncology Drugs Product
Table 62. Novartis Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Oncology Drugs Product
Table 67. Bristol-Myers Squibb Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Development
Table 69. Johnson & Johnson Company Details
Table 70. Johnson & Johnson Business Overview
Table 71. Johnson & Johnson Oncology Drugs Product
Table 72. Johnson & Johnson Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 73. Johnson & Johnson Recent Development
Table 74. Merck & Co. Company Details
Table 75. Merck & Co. Business Overview
Table 76. Merck & Co. Oncology Drugs Product
Table 77. Merck & Co. Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 78. Merck & Co. Recent Development
Table 79. AstraZeneca Company Details
Table 80. AstraZeneca Business Overview
Table 81. AstraZeneca Oncology Drugs Product
Table 82. AstraZeneca Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 83. AstraZeneca Recent Development
Table 84. Pfizer Company Details
Table 85. Pfizer Business Overview
Table 86. Pfizer Oncology Drugs Product
Table 87. Pfizer Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 88. Pfizer Recent Development
Table 89. Amgen Company Details
Table 90. Amgen Business Overview
Table 91. Amgen Oncology Drugs Product
Table 92. Amgen Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 93. Amgen Recent Development
Table 94. Eli Lilly Company Details
Table 95. Eli Lilly Business Overview
Table 96. Eli Lilly Oncology Drugs Product
Table 97. Eli Lilly Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 98. Eli Lilly Recent Development
Table 99. AbbVie Company Details
Table 100. AbbVie Business Overview
Table 101. AbbVie Oncology Drugs Product
Table 102. AbbVie Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 103. AbbVie Recent Development
Table 104. Takeda Company Details
Table 105. Takeda Business Overview
Table 106. Takeda Oncology Drugs Product
Table 107. Takeda Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 108. Takeda Recent Development
Table 109. Astellas Company Details
Table 110. Astellas Business Overview
Table 111. Astellas Oncology Drugs Product
Table 112. Astellas Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 113. Astellas Recent Development
Table 114. Ipsen Company Details
Table 115. Ipsen Business Overview
Table 116. Ipsen Oncology Drugs Product
Table 117. Ipsen Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 118. Ipsen Recent Development
Table 119. Sanofi Company Details
Table 120. Sanofi Business Overview
Table 121. Sanofi Oncology Drugs Product
Table 122. Sanofi Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 123. Sanofi Recent Development
Table 124. Bayer Company Details
Table 125. Bayer Business Overview
Table 126. Bayer Oncology Drugs Product
Table 127. Bayer Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 128. Bayer Recent Development
Table 129. Biogen Idec Company Details
Table 130. Biogen Idec Business Overview
Table 131. Biogen Idec Oncology Drugs Product
Table 132. Biogen Idec Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 133. Biogen Idec Recent Development
Table 134. Teva Company Details
Table 135. Teva Business Overview
Table 136. Teva Oncology Drugs Product
Table 137. Teva Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 138. Teva Recent Development
Table 139. Otsuka Company Details
Table 140. Otsuka Business Overview
Table 141. Otsuka Oncology Drugs Product
Table 142. Otsuka Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 143. Otsuka Recent Development
Table 144. Eisai Company Details
Table 145. Eisai Business Overview
Table 146. Eisai Oncology Drugs Product
Table 147. Eisai Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 148. Eisai Recent Development
Table 149. Merck KGaA Company Details
Table 150. Merck KGaA Business Overview
Table 151. Merck KGaA Oncology Drugs Product
Table 152. Merck KGaA Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 153. Merck KGaA Recent Development
Table 154. Gilead Sciences Company Details
Table 155. Gilead Sciences Business Overview
Table 156. Gilead Sciences Oncology Drugs Product
Table 157. Gilead Sciences Revenue in Oncology Drugs Business (2020-2025) & (US$ Million)
Table 158. Gilead Sciences Recent Development
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
Table 162. Authors List of This Report
List of Figures
Figure 1. Oncology Drugs Picture
Figure 2. Global Oncology Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oncology Drugs Market Share by Type: 2024 VS 2031
Figure 4. Chemotherapy Features
Figure 5. Targeted Therapy Features
Figure 6. Immunotherapy (Biologic Therapy) Features
Figure 7. Hormonal Therapy Features
Figure 8. Others Features
Figure 9. Global Oncology Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Oncology Drugs Market Share by Application: 2024 VS 2031
Figure 11. Blood Cancer Case Studies
Figure 12. Breast Cancer Case Studies
Figure 13. Gastrointestinal Cancer Case Studies
Figure 14. Prostate Cancer Case Studies
Figure 15. Respiratory or Lung Cancer Case Studies
Figure 16. Others Case Studies
Figure 17. Oncology Drugs Report Years Considered
Figure 18. Global Oncology Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Oncology Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Oncology Drugs Market Share by Region: 2024 VS 2031
Figure 21. Global Oncology Drugs Market Share by Players in 2024
Figure 22. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2024)
Figure 23. The Top 10 and 5 Players Market Share by Oncology Drugs Revenue in 2024
Figure 24. North America Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. North America Oncology Drugs Market Share by Country (2020-2031)
Figure 26. United States Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Canada Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Oncology Drugs Market Share by Country (2020-2031)
Figure 30. Germany Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Nordic Countries Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Oncology Drugs Market Share by Region (2020-2031)
Figure 38. China Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Japan Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. South Korea Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Australia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Oncology Drugs Market Share by Country (2020-2031)
Figure 46. Mexico Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Brazil Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Oncology Drugs Market Share by Country (2020-2031)
Figure 50. Turkey Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. UAE Oncology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Roche Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 54. Celgene Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 55. Novartis Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 57. Johnson & Johnson Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 58. Merck & Co. Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 59. AstraZeneca Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 60. Pfizer Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 61. Amgen Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 62. Eli Lilly Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 63. AbbVie Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 64. Takeda Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 65. Astellas Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 66. Ipsen Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 67. Sanofi Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 68. Bayer Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 69. Biogen Idec Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 70. Teva Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 71. Otsuka Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 72. Eisai Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 73. Merck KGaA Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 74. Gilead Sciences Revenue Growth Rate in Oncology Drugs Business (2020-2025)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
